Bayer Sees Positive Consumer Change From COVID-19 Despite Slowing Sales
Bayer says the growing interest in self-care triggered by the coronavirus outbreak is here to stay, with demand showing no sign of slowing for dietary supplements as consumers look to give their immune systems a boost. While Bayer benefited from this in the second quarter, sales across its other Consumer Health categories went into reverse as a result of lockdowns and social distancing measures.
You may also be interested in...
Bayer posts double-digit rise in Q1 Consumer Health sales off the back of unprecedented demand for its dietary supplements in the middle of the global coronavrius pandemic.
Bayer's Consumer Health chief Heiko Schipper is hoping a focus on innovation and a leaner portfolio will help return the business to mid-single-digit growth by 2022. The German firm has identified its North American business as the 'key area to fix'.
Nestlé Health Science is expanding its CBD offering outside the US with the UK launch of a dietary supplement formulated by cannabis development firm Geocann.